Literature DB >> 25216046

Sphingosine kinase 1 isoform-specific interactions in breast cancer.

Daniel Yagoub1, Marc R Wilkins, Angelina J Lay, Dominik C Kaczorowski, Diana Hatoum, Sarah Bajan, Gyorgy Hutvagner, Jack H Lai, Wengen Wu, Rosetta Martiniello-Wilks, Pu Xia, Eileen M McGowan.   

Abstract

Sphingosine kinase 1 (SK1) is a signaling enzyme that catalyzes the formation of sphingosine-1-phosphate. Overexpression of SK1 is causally associated with breast cancer progression and resistance to therapy. SK1 inhibitors are currently being investigated as promising breast cancer therapies. Two major transcriptional isoforms, SK143 kDa and SK151 kDa, have been identified; however, the 51 kDa variant is predominant in breast cancer cells. No studies have investigated the protein-protein interactions of the 51 kDa isoform and whether the two SK1 isoforms differ significantly in their interactions. Seeking an understanding of the regulation and role of SK1, we used a triple-labeling stable isotope labeling by amino acids in cell culture-based approach to identify SK1-interacting proteins common and unique to both isoforms. Of approximately 850 quantified proteins in SK1 immunoprecipitates, a high-confidence list of 30 protein interactions with each SK1 isoform was generated via a meta-analysis of multiple experimental replicates. Many of the novel identified SK1 interaction partners such as supervillin, drebrin, and the myristoylated alanine-rich C-kinase substrate-related protein supported and highlighted previously implicated roles of SK1 in breast cancer cell migration, adhesion, and cytoskeletal remodeling. Of these interactions, several were found to be exclusive to the 43 kDa isoform of SK1, including the protein phosphatase 2A, a previously identified SK1-interacting protein. Other proteins such as allograft inflammatory factor 1-like protein, the latent-transforming growth factor β-binding protein, and dipeptidyl peptidase 2 were found to associate exclusively with the 51 kDa isoform of SK1. In this report, we have identified common and isoform-specific SK1-interacting partners that provide insight into the molecular mechanisms that drive SK1-mediated oncogenicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25216046      PMCID: PMC5414788          DOI: 10.1210/me.2013-1423

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  90 in total

1.  Identification of novel 14-3-3ζ interacting proteins by quantitative immunoprecipitation combined with knockdown (QUICK).

Authors:  Feng Ge; Wen-Liang Li; Li-Jun Bi; Sheng-Ce Tao; Zhi-Ping Zhang; Xian-En Zhang
Journal:  J Proteome Res       Date:  2010-09-29       Impact factor: 4.466

2.  A critical role for the protein phosphatase 2A B'α regulatory subunit in dephosphorylation of sphingosine kinase 1.

Authors:  Melissa R Pitman; Renae K Barr; Briony L Gliddon; Angus M Magarey; Paul A B Moretti; Stuart M Pitson
Journal:  Int J Biochem Cell Biol       Date:  2010-11-11       Impact factor: 5.085

3.  Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK).

Authors:  Matthias Selbach; Matthias Mann
Journal:  Nat Methods       Date:  2006-10-29       Impact factor: 28.547

4.  Sphingosine kinase-1 is cleaved by cathepsin B in vitro: identification of the initial cleavage sites for the protease.

Authors:  Tarek A Taha; Mazen El-Alwani; Yusuf A Hannun; Lina M Obeid
Journal:  FEBS Lett       Date:  2006-10-12       Impact factor: 4.124

5.  Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes.

Authors:  S M Pitson; R J D'andrea; L Vandeleur; P A Moretti; P Xia; J R Gamble; M A Vadas; B W Wattenberg
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

6.  Sphingosine kinase transmits estrogen signaling in human breast cancer cells.

Authors:  Olga A Sukocheva; Lijun Wang; Nathaniel Albanese; Stuart M Pitson; Mathew A Vadas; Pu Xia
Journal:  Mol Endocrinol       Date:  2003-07-24

7.  Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells.

Authors:  Victor E Nava; John Peyton Hobson; Shvetha Murthy; Sheldon Milstien; Sarah Spiegel
Journal:  Exp Cell Res       Date:  2002-11-15       Impact factor: 3.905

8.  The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane.

Authors:  Catherine M Sutherland; Paul A B Moretti; Niamh M Hewitt; Christopher J Bagley; Mathew A Vadas; Stuart M Pitson
Journal:  J Biol Chem       Date:  2006-03-06       Impact factor: 5.157

9.  Sphingosine kinase as a regulator of calcium entry through autocrine sphingosine 1-phosphate signaling in thyroid FRTL-5 cells.

Authors:  Dan Gratschev; Christoffer Löf; Jari Heikkilä; Anders Björkbom; Pramod Sukumaran; Ari Hinkkanen; J Peter Slotte; Kid Törnquist
Journal:  Endocrinology       Date:  2009-10-01       Impact factor: 4.736

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more
  13 in total

1.  LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages.

Authors:  Junfei Jin; Zhongyang Lu; Yanchun Li; Ji Hyun Ru; Maria F Lopes-Virella; Yan Huang
Journal:  J Leukoc Biol       Date:  2018-06-08       Impact factor: 4.962

2.  TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Authors:  Keith R Stayrook; Justin K Mack; Donna Cerabona; Daniel F Edwards; Hai H Bui; Maria Niewolna; Pierrick Gj Fournier; Khalid S Mohammad; David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-07-08

3.  Supervillin Contributes to LPS-induced Inflammatory Response in THP-1 Cell-derived Macrophages.

Authors:  Jun Zhou; Yuhui Que; Lihua Pan; Xu Li; Chao Zhu; Lai Jin; Shengnan Li
Journal:  Inflammation       Date:  2021-09-03       Impact factor: 4.092

Review 4.  Molecular mechanisms of regulation of sphingosine kinase 1.

Authors:  Michael J Pulkoski-Gross; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-30       Impact factor: 4.698

Review 5.  Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Authors:  Nikolas K Haass; Najah Nassif; Eileen M McGowan
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

6.  Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer.

Authors:  Diana Hatoum; Daniel Yagoub; Alireza Ahadi; Najah T Nassif; Eileen M McGowan
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

Review 7.  Protein Kinase Targets in Breast Cancer.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Int J Mol Sci       Date:  2017-11-27       Impact factor: 5.923

8.  Altered Leukocyte Sphingolipid Pathway in Breast Cancer.

Authors:  Larissa P Maia; Paula S Santos; Patricia T Alves; Cláudia M Rodrigues; Thaíse G Araújo; Yara Cristina P Maia; Alinne Tatiane F Câmara; Luiz Ricardo Goulart
Journal:  Int J Mol Sci       Date:  2017-11-24       Impact factor: 5.923

Review 9.  Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.

Authors:  Diana Hatoum; Nahal Haddadi; Yiguang Lin; Najah T Nassif; Eileen M McGowan
Journal:  Oncotarget       Date:  2017-05-30

Review 10.  Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming.

Authors:  Olga A Sukocheva
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.